Travere Therapeutics and partner CSL Vifor could be weeks away from EU approval of sparsentan for IgA nephropathy, after getting a positive opinion on the drug from the EMA’s human medicines committee ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback